Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc.

SUPNNYSE / NASDAQHealthcareMid cap

$28.61+$0.26 (+0.9%)

Last close · Data as of Nov 20, 2026

Market cap
$2.6B
P/E
-67.3x
EV / EBITDA
58.9x
Revenue
$719.0M
Net margin
-5.4%
ROCE
-3.3%

-36.1% over the last year

Supernus Pharmaceuticals, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-30.6%
3M
-39.7%
6M
-41.2%
1Y
-36.1%
5Y
-14.5%

52-week range

Day change +$0.26 (+0.9%) from $28 to $29 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in SUPN, bought on each weekday since 2021.

News & filings

What Supernus Pharmaceuticals filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 38.5 million US dollars in fiscal 2025.

Strengths (1)

  • The company carries almost no debt: debt to equity of 0.04.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.

Read moreShow less

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

Sector
Healthcare
Shares outstanding
57.5M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$2.6B
P/E
-67.3x
P/B
2.4x
EV / EBITDA
58.9x
EV / Sales
3.5x
P/S
3.6x
52-week high
$56.32
52-week low
$26.16

Profitability

Operating margin
-5.1%
Net margin
-5.4%
EBITDA margin
5.9%
ROE
-3.6%
ROCE
-3.3%
ROA
-2.7%
Asset turnover
0.49

Growth

Revenue
$719.0M
Revenue growth, 1Y
8.6%
Revenue CAGR, 3Y
2.5%
Net profit growth, 1Y
-152.2%
Free cash flow
$46.0M

Solvency

Current ratio
1.90
Debt / Equity
0.04
Debt / Assets
0.03
CFO / Net profit
-1.23
Cash / Market cap
5.0%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$719.0M
Cost of revenue$74.6M
Gross profit$644.4M
Operating expenses$681.3M
Research and development$106.2M
Selling, general and administrative$485.6M
Operating income-$36.9M
Interest and other-$12.2M
Pretax income-$49.0M
Tax and other-$10.5M
Net income-$38.5M

Revenue and net profit

Revenue grew 8.6% in FY2025; net profit is the dashed line.

Supernus Pharmaceuticals, Inc. revenue and net profit by fiscal year
Supernus Pharmaceuticals, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$667.2M$60.7M
FY2023$607.5M$1.3M
FY2024$661.8M$73.9M
FY2025$719.0M-$38.5M

Cash flows

FY2025: $47.3M from operations, $46.0M free after investment (dashed).

Supernus Pharmaceuticals, Inc. operating and free cash flow by fiscal year
Supernus Pharmaceuticals, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$116.8M$116.4M
FY2023$111.1M$110.5M
FY2024$172.0M$171.2M
FY2025$47.3M$46.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$719.0M+8.6%1Y
EBITDA
$42.5M-76.1%1Y
Net profit
-$38.5M-152.2%1Y
Cash from operations
$47.3M-72.5%1Y
Free cash flow
$46.0M-73.1%1Y
Revenue CAGR, 3Y
2.5%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$719.0M$42.5M-$38.5M$46.0M-3.6%+8.6%-152.2%

Monthly returns

Month-by-month returns of SUPN across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.5B
Liabilities$390.9M
Equity$1.1B
Paid-in capital$543.8M
Retained earnings$517.9M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; SUPN highlighted.

P/E against peers

SUPN has no positive P/E; the peer median is 13.5x.

Not shown (no positive earnings and no EV / Sales): Supernus Pharmaceuticals, Inc., Arcus Biosciences, Inc., Acadia Healthcare Company, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Supernus Pharmaceuticals, Inc.SUPNthis company$2.6B-67.3x2.4x-3.6%58.9x
Arcus Biosciences, Inc.RCUS$3.1B-8.8x4.9x-55.9%-8.9x
National HealthCare CorporationNHC$2.9B24.5x2.7x11.2%13.7x
Privia Health Group, Inc.PRVA$2.7B117.5x3.7x3.1%50.4x
TransMedics Group, Inc.TMDX$2.5B13.0x5.2x40.2%16.8x
Acadia Healthcare Company, Inc.ACHC$2.3B-2.1x1.2x-56.6%-6.5x
Prestige Consumer Healthcare Inc.PBH$2.2B11.3x1.1x10.1%9.5x
LeMaitre Vascular, Inc.LMAT$2.1B37.0x5.4x14.7%25.3x
Select Medical Holdings CorporationSEM$2.0B14.0x1.2x8.6%9.2x
Peer median—13.5x3.2x9.3%11.6x

Year-to-date ROI

SUPN since 1 January, against earlier years.

Historical volatility

SUPN's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Supernus Pharmaceuticals, Inc. operating margin by fiscal year
Supernus Pharmaceuticals, Inc. operating margin by fiscal year
DateOperating margin
FY20226.8%
FY20232.2%
FY202411.4%
FY2025-5.1%
LineFY2025
Cost of revenueCost Of Revenue$74.6M
Gross profitGross Profit$644.4M
Operating expensesOperating Expense$681.3M
Research and developmentResearch And Development$106.2M
Depreciation and amortisationDepreciation And Amortization In Income Statement$89.5M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$89.5M
Amortization$89.5M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$89.5M
Total expensesTotal Expenses$755.8M
Pretax incomePretax Income-$49.0M

Learn while you research

Academy chapters picked for Supernus Pharmaceuticals, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →